Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Late-Breaker Poster Presentation to occur at the 39th Annual Society for Immunotherapy of Cancer (SITC) conference on November 9th, 2024 - ...

Therapeutics reports preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, ...

According to the findings, OR502 showed a safety profile without any adverse events reported even at the maximum dose level.

BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+™) and prostate cancer (Bria-PROS+™) generate robust anti-cancer activity in preclinical models Novel therapy activates both ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

November 07, 2024--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S ...

The South Korean platelet rich plasma market is set for substantial growth over the next decade, with a projected compound ...

NEW YORK – Cel-Sci on Thursday said the US Food and Drug Administration agreed with its plan to select head and neck cancer patients with low PD-L1 tumor expression in a confirmatory registrational ...

Researchers from the TEDDY study highlight how specific genetic and environmental factors may drive early autoimmunity linked to type 1 diabetes in children, emphasizing distinct patterns for ...

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced that it will present Phase 1 results for the ...